FTC May Set Parameters Of Acceptable Brand/Generic Reverse Settlements
Executive Summary
While the Federal Trade Commission is continuing its battle against reverse settlements, the agency concedes that not all deals are anticompetitive - and it would like to delineate which ones are acceptable
You may also be interested in...
Pfizer Settlement With Ranbaxy Delays Generic Lipitor Entry
Pfizer expects to hold off generic competition for Lipitor (atorvastatin) in the United States until November 2011 under a settlement agreement with Ranbaxy
Pfizer Settlement With Ranbaxy Delays Generic Lipitor Entry
Pfizer expects to hold off generic competition for Lipitor (atorvastatin) in the United States until November 2011 under a settlement agreement with Ranbaxy
House Bill Banning “Reverse Settlements” Would Give FTC Exemption Power
A bill introduced by Rep. Bobby Rush, D-Ill., banning "reverse" settlements between brand and generic companies would give the Federal Trade Commission the power to allow any such agreement it deems furthers market competition